Description
EvroPlus Everolimus stent is a coating consisting of a blend of Everolimus drug (the active ingredient) and biodegradable polymers (the inactive ingredient).
Everolimus is a Macrocyclic lactone produced by Streptomyces hygroscopicus.
EvroPlus has proven drug release kinetics Initial Burst Release of 30% to 40% Everolimus in the first week followed by sustained release up to 90 days to maintain therapeutic Everolimus drug concentration to optimize the anti-tissue proliferative action.
Reviews
There are no reviews yet.